Navigation Links
Data shows VisionGate's 3D imaging platform accurately detects lung cancer in sputum
Date:10/28/2013

Sydney, Australia and Phoenix, AZ, USA October 28, 2013 VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer.

The pilot study analyzed sputum samples from patients with confirmed lung cancer and from healthy individuals. The results show that VisionGate's Cell-CT platform and LuCED sputum test accurately detected the presence or absence of lung cancer cells in patient sputum from a spontaneous cough. In the 53 individuals studied to date, LuCED and the Cell-CT achieved a sensitivity of more than 95% and specificity of 99.8%. The high sensitivity indicates that the Cell-CT detects most cancers, and the high specificity means that the rate of false positive readings is exceedingly low. This is far greater accuracy than has been demonstrated with any other lung cancer screening test.

"Lung cancer remains the leading cause of cancer death in the U.S., primarily because it is not detected until after the cancer has spread," commented Alan Nelson, Ph.D., Founder and CEO of VisionGate. "Results to date from this ongoing clinical study suggest that LuCED and the Cell-CT correctly identify more than nine out of every ten cases of lung cancer with virtually no false positive results, supporting the goal of developing a new lung cancer screening paradigm that is both accurate and cost-effective."

The automated Cell-CT platform creates strikingly clear and comprehensive 3D digital images of the cells contained in sputum. It uses advanced algorithms to identify the presence or absence of cell biosignatures associated with malignant or normal status, making it possible to determine with great accuracy whether or not an individual has cancer.

Low-dose x-ray computed tomography (CT) screening can detect lung cancer at early stages and save lives. But x-ray CT screening has a very high rate of false positive results, which can require costly and invasive follow-up procedures. The large National Cancer Institute (NCI) National Lung Screening Trial showed that more than 96% of the "positive" results from x-ray CT screening were actually false positives. As a result, its use is recommended only in the highest-risk individuals. The potential ability of VisionGate's Cell-CT platform to non-invasively and cost-effectively confirm or refute positive results from x-ray CT scans would make widespread use of lung cancer screening far more feasible.

Glen J. Weiss, M.D., Director of Clinical Research, Cancer Treatment Centers of America Western Regional Medical Center, noted, "The urgency of developing accurate, cost-effective tools for early detection of lung cancer is highlighted by the thousands of preventable lung cancer deaths each year. This data showing that the Cell-CT platform can detect lung cancer with high accuracy from sputum samples in patients at all stages of the disease, as well as identifying those who are cancer-free, is very encouraging. We look forward to continuing to work with VisionGate to enlarge the study population and generate the data needed to advance development of this promising lung cancer screening test."

Previous studies had confirmed that analyzing cells in sputum could be useful in the early detection of lung cancer. However, the typically poor sensitivity of raw sputum analysis and the labor-intensive nature of the process made it impracticable for widespread use. The Cell-CT's high resolution 3D technology and its automated image analysis software for the first time make a cell-based diagnostic approach using sputum samples logistically feasible and cost-effective.

Scarlett Spring, President of VisionGate, added, "We soon expect to supplement these exciting efficacy results with peer-reviewed economic analysis data that confirm the cost-effectiveness of our approach. We also are expanding our collaborative efforts with a variety of institutions as we focus on generating the additional data needed to gain FDA regulatory clearance of LuCED and the Cell-CT platform for adjunctive use with x-ray CT screening, and then possibly as a stand-alone test for lung cancer screening that would be readily available at moderate cost to the broader population."


'/>"/>

Contact: Barbara Lindheim
blindheim@bllbiopartners.com
917-355-9234
BLL Partners, LLC
Source:Eurekalert  

Related medicine news :

1. Wellesley study shows income inequality a key factor in high US teen births
2. Invasive heart test being dramatically overused, Stanford study shows
3. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
4. Lung Cancer Screening Might Pay Off, Analysis Shows
5. Nonsurgical Method to Measure Brain Pressure Shows Promise
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Study Shows New Option for Kids With Tough-to-Treat Leukemia
8. Politics May Get in the Way of Empathy, Research Shows
9. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
10. Experimental Pill for Multiple Sclerosis Shows Promise
11. Mechanical tissue resuscitation technology shows promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Data shows VisionGate's 3D imaging platform accurately detects lung cancer in sputum
(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... Most us ... concern, but a new study from the Osteoarthritis Initiative shows that certain ... knee osteoarthritis. Knowing this in advance may give doctors the opportunity to treat patients ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... week to review more than eighty-nine grant submissions all vying for nearly $1,000,000 ... in the Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... is sharing bold recipes for Memorial Day entertaining that are sure to satisfy ... “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly balanced recipes ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Radiology has become the number one diagnostic ... spiraled to the number one ranking as a result.  ... before as the most complete and reliable method for ... back pain an MRI may confirm a suspected herniated ... in entirely different treatment protocols.  In these circumstances, patients ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
Breaking Medicine Technology: